Alzheimer's Research UK Oxford Drug Discovery Institute
THE ALZHEIMER’S RESEARCH UK OXFORD DRUG DISCOVERY INSTITUTE COUPLES THE DEEP DISEASE KNOWLEDGE AND BIOLOGY EXPERTISE OF THE ACADEMIC COMMUNITY WITH HIGH QUALITY, INNOVATIVE DRUG DISCOVERY TECHNOLOGIES.
Overview
Established in 2015, the Oxford Drug Discovery Institute is part of an alliance of three drug discovery institutes (Oxford, Cambridge, UCL) funded by Alzheimer's Research UK. Our goal is to validate novel targets that may show therapeutic promise for Alzheimer's disease and other neurodegenerative conditions, prosecute screening campaigns to identify chemical hits, and develop these into leads for development by industrial collaborators.
The ODD is located within the Centre for Medicines Discovery, Nuffield Department of Medicine at the University of Oxford Old Road Campus. We are looking for academic researchers who have targets and ideas with translational potential, and who wish to fast-track these ideas towards new medicines.
Our current focus is on targets that influence neuroinflammatory processes and organelle dysfunction in Alzheimer's and Parkinson's disease, as well as other neurodegenerative conditions. We have a core biology team with expertise in validating targets using iPSC technologies, and a dedicated assay development and screening team, who support our portfolio of projects and develop bespoke screening assays to identify compounds that can be developed by our medicinal chemists.
For further information, please contact our Chief Scientific Officer, Dr Emma Mead (emma.mead@cmd.ox.ac.uk), or our Assistant Project Manager, Kate Humphrey (kate.humphrey@cmd.ox.ac.uk)